Page last updated: 2024-11-06

4-methoxybenzohydrazide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-Methoxybenzohydrazide is a synthetic compound that has been investigated for its potential biological activities. It can be synthesized through a variety of methods, often involving the reaction of 4-methoxybenzoic acid with hydrazine hydrate. Research has shown that 4-methoxybenzohydrazide exhibits anti-inflammatory, analgesic, and antioxidant properties. These properties are likely due to its ability to inhibit the production of inflammatory mediators and reactive oxygen species. 4-methoxybenzohydrazide is studied for its potential therapeutic applications in conditions such as inflammation, pain, and oxidative stress-related diseases. It is also being investigated for its potential anticancer and antimicrobial activities.'

4-methoxybenzohydrazide: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID76792
CHEMBL ID1588015
SCHEMBL ID407188
MeSH IDM000609396

Synonyms (77)

Synonym
anisoylhydrazine
p-methoxybenzoic hydrazide
nsc 76223
benzoic acid, 4-methoxy-, hydrazide
p-anisohydrazide ,
einecs 221-952-5
anisic acid hydrazide
p-anisic hydrazide
anisic hydrazide
4-methoxybenzoylhydrazine
brn 0389017
benzoic acid, p-methoxy-, hydrazide
4-methoxybenzoyl hydrazide
33bk77102i ,
4-10-00-00454 (beilstein handbook reference)
unii-33bk77102i
4meophcon2
4-methoxybenzohydrazide
4-methoxybenzoic acid, hydrazide
3290-99-1
(p-methoxybenzoyl)hydrazine
p-anisoylhydrazine
wln: zmvr do1
hydrazine, 4-methoxybenzoyl-
nsc-76223
nsc76223
4-methoxybenzoic acid hydrazide
p-methoxybenzoic acid hydrazide
(4-methoxybenzoyl)hydrazine
(4-methoxybenzoyl)hydrazide
p-anisic acid, hydrazide
OPREA1_578754
OPREA1_834050
STK089128
4-methoxybenzhydrazide, 97%
MLS000833598
smr000457119
4-methoxybenzene-1-carbohydrazide
p-anisic acid hydrazide
M1770
AKOS000194883
CHEMBL1588015 ,
HMS2804K19
NCGC00246653-01
4-methoxybenzohydrazide;4-methoxybenzhydrazide
A821514
bdbm50340089
4-methoxy-benzohydrazide
BBL005388
p-methoxybenzhydrazide
p-methoxy benzhydrazide
4-methoxy benzhydrazide
4-methoxybenzhydrazide
4-methoxybenzoic hydrazide
FT-0618917
AM20040183
SCHEMBL407188
4-methoxy-benzoic acid hydrazide
anisohydrazide
4-methoxybenzohydrazide #
W-106806
STR02684
p-anisoylhydrazide
p-methoxybenzohydrazide
p-methoxybenzoyl hydrazide
methoxybenzhydrazide, 4-
F1335-0033
DTXSID60186556
p-methoxy benzohydrazide
303084-44-8
mfcd00017073
SY005826
I11428
Q27256258
CS-0116725
EN300-18129
Z57199662
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATAD5 protein, partialHomo sapiens (human)Potency23.09990.004110.890331.5287AID504467
USP1 protein, partialHomo sapiens (human)Potency35.48130.031637.5844354.8130AID743255
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency2.81840.00798.23321,122.0200AID2551
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cathepsin HCapra hircus (goat)Ki588.00008.20008.20008.2000AID1125412
Cathepsin B Capra hircus (goat)Ki0.64000.00000.63811.9000AID1125410
Carbonic anhydrase 1Homo sapiens (human)Ki7.84000.00001.372610.0000AID589727
Carbonic anhydrase 2Homo sapiens (human)Ki5.75000.00000.72369.9200AID589728
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (12)

Processvia Protein(s)Taxonomy
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (27)

Assay IDTitleYearJournalArticle
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1059234Lipophilicity, log P of the compound2013European journal of medicinal chemistry, , Volume: 70Comparison of Multiple Linear Regressions and Neural Networks based QSAR models for the design of new antitubercular compounds.
AID1125408Inhibition of cathepsin H in goat liver assessed as residual enzyme activity using Leu-betaNA as substrate at 0.1 x 10'-4 M after 30 mins by colorimetric analysis relative to control2014European journal of medicinal chemistry, Apr-22, Volume: 77Acyl hydrazides and triazoles as novel inhibitors of mammalian cathepsin B and cathepsin H.
AID589732Selectivity ratio of Ki for human cytosolic carbonic anhydrase 2 to Ki for Candida albicans Nce103 beta-carbonic anhydrase2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Carbonic anhydrase inhibitors. Inhibition of the β-class enzymes from the fungal pathogens Candida albicans and Cryptococcus neoformans with branched aliphatic/aromatic carboxylates and their derivatives.
AID589727Inhibition of human cytosolic carbonic anhydrase 1 by stopped flow CO2 hydration assay2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Carbonic anhydrase inhibitors. Inhibition of the β-class enzymes from the fungal pathogens Candida albicans and Cryptococcus neoformans with branched aliphatic/aromatic carboxylates and their derivatives.
AID1059233Antitubercular activity against Mycobacterium tuberculosis BCG2013European journal of medicinal chemistry, , Volume: 70Comparison of Multiple Linear Regressions and Neural Networks based QSAR models for the design of new antitubercular compounds.
AID589729Inhibition of Cryptococcus neoformans Can2 beta-carbonic anhydrase by stopped flow CO2 hydration assay2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Carbonic anhydrase inhibitors. Inhibition of the β-class enzymes from the fungal pathogens Candida albicans and Cryptococcus neoformans with branched aliphatic/aromatic carboxylates and their derivatives.
AID1125404Inhibition of cathepsin B in goat liver assessed as residual enzyme activity using alpha-N-benzoyl-D,L-arginine-2-naphthylamide as substrate at 0.1 x 10'-4 M pretreated with enzyme for 30 mins prior to substrate challenge by colorimetric analysis relative2014European journal of medicinal chemistry, Apr-22, Volume: 77Acyl hydrazides and triazoles as novel inhibitors of mammalian cathepsin B and cathepsin H.
AID1125402In vitro inhibition of cysteine protease in goat liver homogenate assessed as residual endogenous proteolytic activity at 0.1 mM at pH 5.0 after 3 hrs relative to control2014European journal of medicinal chemistry, Apr-22, Volume: 77Acyl hydrazides and triazoles as novel inhibitors of mammalian cathepsin B and cathepsin H.
AID589730Inhibition of Candida albicans Nce103 beta-carbonic anhydrase by stopped flow CO2 hydration assay2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Carbonic anhydrase inhibitors. Inhibition of the β-class enzymes from the fungal pathogens Candida albicans and Cryptococcus neoformans with branched aliphatic/aromatic carboxylates and their derivatives.
AID1125403In vitro inhibition of cysteine protease in goat liver homogenate assessed as residual endogenous proteolytic activity at 0.1 mM at pH 5.0 after 24 hrs relative to control2014European journal of medicinal chemistry, Apr-22, Volume: 77Acyl hydrazides and triazoles as novel inhibitors of mammalian cathepsin B and cathepsin H.
AID1125412Non-competitive inhibition of cathepsin H in goat liver using Leu-betaNA as substrate by colorimetric analysis2014European journal of medicinal chemistry, Apr-22, Volume: 77Acyl hydrazides and triazoles as novel inhibitors of mammalian cathepsin B and cathepsin H.
AID589728Inhibition of human cytosolic carbonic anhydrase 2 by stopped flow CO2 hydration assay2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Carbonic anhydrase inhibitors. Inhibition of the β-class enzymes from the fungal pathogens Candida albicans and Cryptococcus neoformans with branched aliphatic/aromatic carboxylates and their derivatives.
AID1125410Competitive inhibition of cathepsin B in goat liver using alpha-N-benzoyl-D,L-arginine-2-naphthylamide as substrate by colorimetric analysis2014European journal of medicinal chemistry, Apr-22, Volume: 77Acyl hydrazides and triazoles as novel inhibitors of mammalian cathepsin B and cathepsin H.
AID589731Selectivity ratio of Ki for human cytosolic carbonic anhydrase 2 to Ki for Cryptococcus neoformans Can2 beta-carbonic anhydrase2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Carbonic anhydrase inhibitors. Inhibition of the β-class enzymes from the fungal pathogens Candida albicans and Cryptococcus neoformans with branched aliphatic/aromatic carboxylates and their derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (11.11)29.6817
2010's7 (77.78)24.3611
2020's1 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.21 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]